As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new analysis finds a large majority of Canadian groups that submitted comments about pending government coverage for medicines also held conflicts with drug makers.

Specifically, 87 percent of comments were made by Canadian groups that had a conflict of interest, such as industry backing. And of those comments, 86 percent involved a conflict with the drug maker that was marketing the medicine being reviewed by the Common Drug Review and panCanadian Oncology Drug Review. These agencies make recommendations to provincial and federal drug plans about funding coverage.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy